The tumorigenic activity of BMI1 also appeared to be independent of ARF signaling in human ovarian cancer cells, where genetic or pharmacological BMI1 inhibition impaired clonal growth without affecting expression of the CDKN2A locus or ARF protein stability [111]. This evidence concerns the gene CDKN2A and ovarian cancer.